S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Investing.com -- Bausch + Lomb Corporation (NYSE:BLCO) saw its shares plunge 10.4% after the eye health company reported first-quarter earnings that fell short of analyst estimates, despite revenue growth.
The company posted an adjusted loss per share of $0.07 for Q1 2025, missing the consensus estimate of $0.02 earnings per share. Revenue came in at $1.14 billion, slightly below expectations of $1.15 billion but up 3% YoY and 5% on a constant currency basis.
Bausch + Lomb’s Vision Care segment, its largest by revenue, grew 3% to $656 million, driven by increased sales of daily contact lenses and over-the-counter eye care products. The Surgical segment saw 9% growth to $214 million, while Pharmaceuticals revenue remained flat at $267 million.
"Our core business is performing well, and we remain focused on positioning the company for long-term, profitable growth," said CEO Brent Saunders.
However, the company reported a GAAP net loss of $212 million for the quarter, widening from a $167 million loss in Q1 2024. Adjusted EBITDA excluding acquired IPR&D fell to $126 million from $180 million a year ago.
Bausch + Lomb updated its full-year 2025 guidance to reflect the estimated one-time impact of a voluntary recall of certain intraocular lenses. It now expects revenue of $5.0-$5.1 billion, up from its previous forecast of $4.95-$5.05 billion.
The sharp stock decline suggests investors were disappointed by the earnings miss and lowered profitability outlook, despite the raised revenue guidance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.